INOVIO PHARMACEUTICALS, INC. (INO) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$1.01

From 52W high−61.54%

Volume2.09M

Market cap$103.40M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$1.01

From 52W high

−61.54%

Volume

2.09M

Market cap

$103.40M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

P/E (TTM)

—

RSI (14)

39.5

MomentumView details →

1D Return

+1.00%

YTD Return

−42.24%

SummaryUpdated Jun 1, 2026

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is a biotechnology company founded in 1979 and headquartered in Plymouth Meeting, Pennsylvania. The company went public in 1998 and has spent over four decades developing DNA-based medicines to treat diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Inovio is currently focused on advancing its lead product candidate INO-3107 toward commercialization, with plans to submit a Biologics License Application to the FDA in mid-2025 for treating recurrent respiratory papillomatosis, a rare HPV-related condition.

Ask drillr about INOVIO PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

23.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−1542.57%

ROA (TTM)

−136.52%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−100.00%

EPS YoY

+99.87%

FCF YoY

+14.87%

Revenue CAGR 3Y

−81.47%

EPS CAGR 3Y

+54.18%

EBITDA YoY

+23.98%

MomentumView details →

1D Return

+1.00%

YTD Return

−42.24%

1Y Return

−59.31%

RSI (14)

39.5

vs 50D SMA

−14.09%

vs 200D SMA

−22.56%

Capital & dividendView details →

Debt/Equity

1.83x

Current Ratio

1.00x

Quick Ratio

1.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.07

EPS Surprise

67.69%

Beats (12Q)

8/12

Next Q EPS Est

−$0.18

Avg Surprise (4Q)

66.03%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−67.43M

Op. CF (TTM)

−80.58M

Next earningsNov 10, 2026 →

Latest newsMore news →

The U.S. Food and Drug Administration completed several key steps in its review of Inovio Pharmaceuticals' biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis.68d ago

Similar companies

LENZ Therapeutics, Inc.LENZ Black Diamond Therapeutics, Inc.BDTX enGene Holdings Inc.ENGN vTv Therapeutics Inc.VTVT Cibus, Inc.CBUS PolyPid Ltd.PYPD Find similar companies →

Latest newsMore news →

Inovio Pharmaceuticals reported first-half 2026 revenue of 1.137 billion yuan, up 55.5% year-over-year, with net profit attributable to shareholders of 246 million yuan versus a net loss of 30 million yuan in the first half of 2025.56d ago The U.S. Food and Drug Administration completed several key steps in its review of Inovio Pharmaceuticals' biologics license application for INO-3107, an investigational treatment for recurrent respiratory papillomatosis.68d ago